ArticleJournal of applied clinical medical physics2026
Evaluation of the efficacy of plan adaptation in stereotactic body proton therapy for pancreatic cancer.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeThis study aimed to quantitatively evaluate the efficacy of plan adaptation in stereotactic body proton therapy (SBPT) for pancreatic cancer using daily CT-based dose evaluation, investigate the appropriate adaptation frequency.
methodsThis retrospective planning study included 10 patients previously treated with X-ray stereotactic body radiation therapy for pancreatic cancer. An initial SBPT plan was created for each patient, using robust optimization with two posterior oblique beams. The prescribed dose was D90 ≥ 40 Gy(RBE) to the CTV_EVAL (the CTV excluding the gastrointestinal [GI] tract plus a 5-mm margin), delivered in five fractions. Daily dose evaluation (DDE) was performed using five daily CT (dCT) images per patient. An adaptive plan (AP) was generated and applied to subsequent fractions if target coverage or organs at-risk (OARs) constraints were not met; otherwise, the initial plan (IP) was employed. Non-adaptation (NA) and daily adaptation (DA) strategies were compared in terms of dose-volume metrics, accumulated doses, tumor control probability (TCP), and normal tissue complication probability (NTCP).
resultsAcross 50 fractions, plan adaptation was necessary in 21 fractions (42%), with a mean of 2.1 adaptations per patient. DA significantly improved target coverage on DDE compared with NA (p < 0.05). Doses to the OARs, particularly the GI tract, were significantly reduced with DA. In the accumulated dose, DA led to a significantly higher D90 of CTV_EVAL (p < 0.05), whereas doses to the OARs demonstrated no significant differences between strategies. TCP was significantly improved with DA, whereas NTCP demonstrated no significant differences for any OARs.
conclusionsThe DA strategy, according to DDE, improved target dose coverage while maintaining or reducing doses to the OARs. These findings indicate that appropriately frequent plan adaptation-an average of 2.1 adaptations per patient-may improve SBPT safety and efficacy for pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.